Almost every PBMC purchasing conversation eventually arrives at the same question, and it is usually asked too late: fresh or frozen. The honest answer is that it depends on what you are measuring, and that the wrong choice is expensive in a way that does not show up until the data does.
What cryopreservation actually does to a PBMC
Freezing is not storage. It is a process the cell has to survive, and the cells that come out are not a random sample of the cells that went in.
Three things happen. Ice forms, and if it forms inside the cell rather than around it the cell does not recover. Solutes concentrate as water leaves the liquid phase, exposing membranes to osmotic stress. And DMSO, the agent that prevents the first two problems, is itself toxic above a few degrees, which is why handling time at room temperature is a variable rather than a detail.
The populations do not survive equally. Monocytes are the most fragile of the major PBMC subsets and their recovery is routinely lower than their input frequency. Which means a thawed PBMC preparation is subtly enriched for lymphocytes relative to the fresh preparation it came from, before you have done anything to it.
Where the difference shows up in your data
| Assay type | Tolerates cryopreservation | What to watch |
|---|---|---|
| Immunophenotyping by flow | Generally yes | Subset ratios shift if monocyte loss is not accounted for |
| T cell function, ELISpot, ICS | Yes, with a proper rest period | Skipping the rest step is the most common cause of a poor result |
| NK cytotoxicity | Yes, with caveats | Activity is reduced immediately post-thaw and recovers with rest |
| Monocyte and macrophage work | Poorly | The subset you need is the one that survives least well |
| Dendritic cell differentiation | Poorly | Depends on the same fragile monocyte input |
| Whole-blood-adjacent kinetics | No | Any readout sensitive to activation state is affected |
The pattern is simple enough to state as a rule. If the assay reads a stable surface phenotype, freezing is usually fine. If it reads a functional response, freezing is fine provided the cells are rested. If it depends on monocytes, fresh is the safer starting point.
The rest period nobody budgets for
Thawed PBMCs are not ready to assay. Cells that survived the thaw are still carrying damage, and the ones that did not survive are releasing debris and DNA that will clump the preparation and drag viable cells down with it. A rest in culture, commonly overnight, lets dying cells complete the process and lets survivors recover function.
This step is skipped constantly, usually because a protocol was written around fresh material and then the material changed. When a frozen lot appears to underperform against a fresh one, the rest period is the first thing to check and it is more often the explanation than the lot.
What the CAR-T literature found
The concern that cryopreserved starting material would compromise manufacture has been tested directly rather than argued. Comparative work manufacturing CAR-T from cryopreserved versus fresh PBMCs found similar functional profiles between the two, with cryopreserved material supporting efficient production. Related work has reported phenotypic differences between fresh and frozen CAR-T infusion products, with fresh products showing higher TIM-3 expression and lower effector T cell content while frozen products retained high anti-tumour potency and specificity.
The practical reading is that cryopreservation is not a barrier to CAR-T manufacture when it is executed properly. The differences that appear are consequences of protocol quality rather than of freezing as such.
Logistics, which is usually the real deciding factor
| Fresh | Cryopreserved | |
|---|---|---|
| Scheduling | Built around the collection date | Built around your calendar |
| Usable window | Short, measured in days | Long, held in vapour-phase liquid nitrogen |
| Multi-site studies | Difficult to synchronise | Straightforward, every site thaws the same lot |
| Repeat-measure designs | Impractical | The reason cryopreservation exists |
| Failed run | The donor collection is gone | Thaw another vial from the same lot |
That last row decides more purchases than any biological argument. A fresh collection that fails is not repeatable. A frozen lot that fails leaves you a second attempt with the variable you care about held constant.
What to specify when you order
Neither format is a single thing, and the specification you receive should reflect that. Worth pinning down before purchase: the format and cell count, whether the material is single donor, what viability figure is documented and whether it is pre-freeze or post-thaw, what donor characterisation ships with it, and what grade it is released under.
OrganaBio documents cryopreserved PBMCs from healthy adult peripheral blood, with the same donor programme behind them as the fresh and cryopreserved leukopaks for programmes that would rather isolate in house. Donor characterisation documents a 14-marker infectious disease screening panel and high-resolution NGS HLA genotyping across HLA-A, B, C, DR, DQ and DP, with KIR genotyping included. Donor selection can be scoped by genotype subject to availability, and eligible donors can be scheduled for repeat collection, which matters when a comparison has to hold the donor constant across a year rather than a week.
Frequently asked questions
Are cryopreserved PBMCs as good as fresh?
For most phenotypic and functional assays, yes, provided the cells are properly cryopreserved and rested after thaw. The exceptions are monocyte-dependent work and dendritic cell differentiation, where monocyte loss during freezing makes fresh material the safer starting point.
Why do I need to rest PBMCs after thawing?
Cells that did not survive the thaw release debris and DNA that clumps the preparation and pulls viable cells down with it, and surviving cells need time to recover function. A rest in culture, commonly overnight, addresses both. Skipping it is the most common reason a frozen lot appears to underperform.
Which PBMC populations survive cryopreservation least well?
Monocytes are the most fragile of the major subsets and recover at lower rates than their input frequency, which subtly enriches a thawed preparation for lymphocytes. Any workflow depending on monocytes, including dendritic cell differentiation, is affected.
Can CAR-T be manufactured from cryopreserved PBMCs?
Yes. Comparative work has found similar functional profiles for CAR-T manufactured from cryopreserved versus fresh PBMCs. Reported differences between fresh and frozen infusion products relate to phenotype and appear to reflect protocol execution rather than freezing as a barrier.
How long can fresh PBMCs be used after collection?
The usable window is short and measured in days rather than weeks, and cell state changes across it. Programmes that cannot build their schedule around a collection date are usually better served by cryopreserved material.
Should I choose fresh or cryopreserved PBMCs?
Choose fresh when the assay runs immediately, depends on monocytes, or reads activation-sensitive kinetics. Choose cryopreserved when the study is multi-site, repeat-measure, scheduled around your own calendar, or when a failed run needs to be repeatable from the same lot.
